FAISAL SUBA: Open Payments
NPI 1598965998 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,163 in 146 payments from 18 companies in 2025. Trend: 2023 $1,865 · 2024 $2,091 · 2025 $3,163
Food & beverage: $3,163
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $543 |
| Otsuka America Pharmaceutical, Inc. | 30 | $500 |
| Alkermes, Inc. | 13 | $387 |
| Teva Pharmaceuticals USA, Inc. | 11 | $347 |
| E.R. Squibb & Sons, L.L.C. | 11 | $241 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $188 |
| ABBVIE INC. | 13 | $178 |
| Janssen Pharmaceuticals, Inc | 7 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $134 |
| Axsome Therapeutics, Inc. | 5 | $109 |
Products named: INGREZZA, REXULTI, ARISTADA, COBENFY, CAPLYTA, UZEDY, VRAYLAR, AUSTEDO XR.
Industry payments across NV — which companies pay providers there.
